GLP-1 Receptor Agonists
21-12-2024
10:30 AM
1 min read

Overview:
Scientists at the World Health Organisation (WHO) have endorsed a new class of medicines known as GLP-1 receptor agonists.
About GLP-1 Receptor Agonists:
- Glucagon-Like Peptide (GLP)-1 receptor agonists mimic a hormone that regulates appetite and blood sugar levels, for managing obesity.
- By specifically binding to the key hormone GLP-1, it regulates blood glucose levels and lipid metabolism.
- This receptor and its agonists hold significant therapeutic potential, reshaping the treatment approaches for multiple diseases, including diabetes, cardiovascular disorders, and neurodegenerative diseases.
- GLP-1 agonists are most often injectable medications, meaning you inject a liquid medication with a needle and syringe.
- The new class of GLP-1 receptor agonists, that included drugs such as semaglutide and tirzepatide, “have the potential to be transformative.
- In medication terms, an agonist is a manufactured substance that attaches to a cell receptor and causes the same action as the naturally occurring substance.
What is GLP-1?
- GLP-1 is a key hormone that plays an integral role in regulating blood glucose levels, lipid metabolism, and several other crucial biological functions.
- It is released by the intestines in response to food intake.

Q1: What is Diabetes?
It is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces.
News: WHO scientists endorse weight loss drugs for controlling obesity: What does it mean for therapies?